Abstract: Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.

Abstract: Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.

Abstract: Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.

Abstract: The invention relates to film-coated tablets containing ibuprofen lysinate with improved stability, bioavailability and higher acceptance (compliance) in patients, and the use of these film-coated tablets for preparing a pharmaceutical composition for the treatment of acute and/or chronic pain.

Abstract: The invention relates to a process for the preparation of endo-nortropine using 8-benzyl-nortropan-3-one perchlorate, as well as the latter product. Endo-nortropine is the key product for the production of important azonia-spironortropanol esters, which are used as pharmaceuticals, particularly spasmolytics. There are three different synthesis methods for the preparation of said intermediate, which lead to different disadvantages. These problems are obviated by the present invention through the two-stage treatment of 8-benzyl-nortropan-3-one perchlorate with catalytically activated hydrogen, the starting product initially being prehydrogenated in aqueous suspension and at atmospheric pressure and ambient pressure with a palladium catalyst, at the end of the reaction the catalyst is recovered by filtration, the filtrate is passed over an anion exchanger and the now alkaline reacting solution is rendered turbulent at 1000 to 1500 r.p.m.

Abstract: A two-piece housing is provided with several bores (3, 4) which extend through the two housing sections (1, 2). Each bore (3, 4) is concentrically surrounded by a centering in each housing section (1, 2), which is in the shape of an internal centering in one housing section and an external centering in the other housing section. These bores (3, 4) are manufactured in each housing section (1, 2) together with the respective concentrically surrounding centering and in one process step with a drilling tool which includes two cutters (8, 9, 10) adapted to the diameters of the bore and the centering respectively. Subsequently, the housing sections (1, 2) provided with the bores (3, 4) and centerings are assembled in such a way that the centerings fittingly interengage. (FIG.

Abstract: A process for the production of endotropine by catalytically reducing tropanone with hydrogen with Raney nickel or Raney copper. This process is conducted with tropanone in an aqueous solution absent of organic solvents, in a closed system, at atmospheric pressure and ambient temperature and subject to turbulent action at 1000 to 1500 r.p.m. The process leads to average yields of 94%. The process improves on prior art processes which use an overpressure and organic solvents which involve a high fire and explosion risk.

Abstract: Compositions of the anticholinergic agent trospium chloride suitable for localized administration are provided, in the form of an aqueous solution having a pH-value of.gtoreq.4.5, that is prepared prior to administration. Methods of using the provided compositions for treating dysfunctions of the bladder and the urinary system are also provided.